Targeting Head and Neck Cancer with Modified Anthrax Toxin
Author Information
Author(s): Schafer Jeffrey M., Peters Diane E., Morley Thomas, Liu Shihui, Molinolo Alfredo A., Leppla Stephen H., Bugge Thomas H.
Primary Institution: National Institute of Dental and Craniofacial Research, National Institutes of Health
Hypothesis
Can a dual uPA and MMP-activated engineered anthrax toxin effectively treat head and neck squamous cell carcinoma?
Conclusion
The engineered anthrax toxin showed strong anti-tumor activity in head and neck squamous cell carcinoma models.
Supporting Evidence
- The engineered toxin caused regression of several xenografted human HNSCC.
- The treatment was well tolerated with minimal side effects.
- Tumor sizes in toxin-treated mice were significantly smaller than in control groups.
- The study demonstrated the potential for targeted cancer therapy using engineered toxins.
Takeaway
Scientists created a special toxin that can help fight a type of throat cancer by making the cancer cells die.
Methodology
The study involved xenografting human HNSCC cell lines into mice and treating them with the engineered toxin.
Potential Biases
Potential bias in the selection of cell lines and animal models used for testing.
Limitations
The study primarily focused on xenograft models, which may not fully replicate human responses.
Participant Demographics
Female athymic nude mice aged 4-6 weeks were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website